EVFM's free cash flow for Q3 2023 was $-2.36M. For the 2023 fiscal year, EVFM's free cash flow was decreased by $78.86M and operating cash flow was $-2.36M. See a summary of the company’s cash flow.

Cash Flow	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Operating Cash Flow	$ -26.69M	$ -70.41M	$ -146.67M	$ -104.83M	$ -55.10M	$ -56.50M
Investing Cash Flow	$ -106.00K	$ -341.00K	$ -2.69M	$ 6.23M	$ -8.12M	$ 2.14M
Financing Cash Flow	$ 8.18M	$ 61.94M	$ 90.69M	$ 154.23M	$ 78.08M	$ 54.42M
Cash Flow From Discontinued Operation	-	-	-	-	-	-
Other Cash Adjustment Inside Changein Cash	-	-	-	-	-	-
End Cash Position	$ 18.88M	$ 4.78M	$ 13.59M	$ 72.25M	$ 16.63M	$ 1.76M
Income Tax Paid Supplemental Data	$ 26.00K	$ 26.00K	$ 11.00K	$ 2.00K	$ 4.00K	$ 2.00K
Interest Paid Supplemental Data	$ 698.00K	$ 698.00K	$ 1.39M	$ 0.00	-	$ 0.00
Issuance Of Capital Stock	$ 7.44M	$ 7.44M	-	$ 107.52M	$ 78.36M	$ 57.54M
Issuance Of Debt	$ 4.12M	$ 5.61M	-	$ 50.00M	$ 0.00	-
Repayment Of Debt	$ -1.00M	$ -5.89M	-	$ 0.00	$ -4.01M	$ 0.00
Free Cash Flow	$ -26.80M	$ -70.75M	$ -149.61M	$ -107.08M	$ -55.26M	$ -56.51M
Domestic Sales	-	-	-	-	-	-
Foreign Sales	-	-	-	-	-	-

Currency in USD

Evofem Biosciences Cash Flow

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing